Mylan Wins Approval of Generic Norvasc
- Share via
Mylan Laboratories Inc. won U.S. regulatory approval for a generic version of Pfizer Inc.’s blood-pressure pill Norvasc.
The Food and Drug Administration confirmed that Mylan was the first to file for approval of generic Norvasc, giving it six months of marketing exclusivity, the Canonsburg, Pa.- based company said.
The period of protected sales will start when Mylan launches its product or when a patent dispute is resolved.
Pfizer is fighting generic Norvasc plans by Mylan and three other companies.
Mylan shares rose $1.02 to $20.40.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
